Rhabdomyolysis as a side effect of simvastatin treatment;Rabdomioliza kao nuspojava liječenja simvastatinom

Acta Medica Croatica

Volumn 59, Issue 4, 2005, Pages 325-328

  Iskra, Bosiljka ^a,b   Živko, Marijana ^b   Kes, Petar ^c  

^a Opća Bolnica Virovitica ^*  (Croatia)

^b Virovitica General Hospital   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Acute renal failure; Adverse effects; Hydroxymethylgluratyl coA reductase inhibitors; Rhabdomyolysis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; HUMAN; HYPERTENSION; MYOPATHY; RHABDOMYOLYSIS; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; MALE; MYOSITIS;

ADULT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; MALE; MYOSITIS; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 33644814384     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. Pedersen TR, Jahnsen KE, Vatn S i sur. Benefits of early lipid-lowering intervention in high-risk patients: The Lipid Intervention Strategies for Coronary Patient Study. Clin Ther 2000; 22: 949-60.
3. Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL-C cholesterol in people with diabetes mellitus: MRC/BHF Heart Protection Study and other major trials. Heart 2000; 84: 357-60.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Sacks FM, Pfeffer MA, Moye LA i sur. For the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
6. Sever PS, Dahlof B, Poulter NR i sur. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.) Lancet 2003; 361: 1149-58.
7. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999; 20: 725-41.
8. Thompson PD, Clarkson P, Karas RH. Statin-Associated Myopathy. JAMA 2003; 289: 1681-90.
9. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-72.
10. Herman RJ. Drug interactions and the statins. CMAJ 1999; 161: 1281-6.
11. Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989; 32: 358-9.
12. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin. Ann Intern Med 1991; 114: 342.
13. Wortmann RL. Proximal weakness of unknown etology. U: Klipell, ur. Rheumatology. London: Mosby, 1998; 7: 163-5.
14. Knochel JP. Catastrophic medical events with exhaustive exerdse: »white collar rhabdomyolysis«. Kidney Int 1990; 38: 709-19.
15. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40.
16. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2002; 35: 1096-107.
17. Shek A, Ferril MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35; 908-17.
18. van Puijenbroek EP, Du Buf-Vereijken PWG, Spooren PFMJ, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996; 240: 403-4.
19. Pogson GW, Kindred LM, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999; 83: 1146.
20. Huić M, Anić B, Čikeš N i sur. Miopatija s rabdomiolizom kao nuspojava istodobnog liječenja s cerivastatinom i gemfibrozilom. Lijec Vjesn 2002; 124: 73-76.